Glargine

ApprovedSmall molecule

Eli Lilly

Glargine is one of 204 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Approved.

Indications

Total Trials

Active Trials

203

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic KetoacidosisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Diabetes MellitusActive, not recruiting

HyperglycemiaActive, not recruiting

Type 2 DiabetesUnknown

Type 1 DiabetesUnknown

Type 1 Diabetes MellitusActive, not recruiting

Diabetic NeuropathyActive, not recruiting

Diabetic KetoacidosisPreclinical

Active, not recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

HyperglycemiaApproved

Active, not recruiting

Type 2 DiabetesPreclinical

Unknown

Type 1 DiabetesPreclinical

Unknown

Type 1 Diabetes MellitusPhase 3

Active, not recruiting

Diabetic NeuropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Glargine

Eli Lilly

Approved

8 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes8 trials

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Completed·DDiabetes Care Center·N/A·NCT00457093·35 enrolled

Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

Completed·MMedanta, The Medicity, India·Phase 4·NCT05457933·250 enrolled

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01215955·1,117 enrolled

Show 5 more trials

Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes

Completed·—·N/A·NCT00978263·47 enrolled

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT01845831·292 enrolled

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT03336528·180 enrolled

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT01378117·90 enrolled

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT02455076·150 enrolled

Type 1 Diabetes4 trials

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

Completed·UUniversity of Colorado, Denver·Phase 4·NCT03107208·61 enrolled

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown status·—·Phase 4·NCT04664764·60 enrolled

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00505882

Show 1 more trial

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Terminated·UUniversity of Texas Southwestern Medical Center·N/A·NCT00564018·33 enrolled

Type 2 Diabetes Mellitus3 trials

A Study in Patients With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01435616·1,538 enrolled

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Completed·XXijing Hospital·N/A·NCT03829891·60 enrolled

The Inova Type 2 Diabetes Mellitus Study

Withdrawn·IInova Health Care Services·N/A·NCT02222623

Diabetic Ketoacidosis3 trials

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Completed·VVanderbilt University Medical Center·N/A·NCT00179127·75 enrolled

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Terminated·—·N/A·NCT02548494·17 enrolled

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Unknown status·—·N/A·NCT05219942·52 enrolled

Medication2 trials

RISE Adult Medication Study

Completed·RRISE Study Group·Phase 3·NCT01779362·267 enrolled

RISE Pediatric Medication Study

Completed·RRISE Study Group·Phase 3·NCT01779375·91 enrolled

17 more indications

Diagnosis1 trial

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis

Unknown status·KKarolinska Institutet·Phase 4·NCT01271517·120 enrolled

Tics1 trial

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00551356·53 enrolled

Effectiveness1 trial

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Completed·UUniversity of Colorado, Denver·Phase 1·NCT01153100·60 enrolled

Efficacy and Safety1 trial

Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM

Completed·—·N/A·NCT01855243·63 enrolled

Diabetes Mellitus1 trial

A Study in Participants With Type I Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01454284·1,114 enrolled

Diabetic Neuropathy1 trial

Evaluation of Exenatide in Patients With Diabetic Neuropathy

Completed·UUniversity of Michigan·N/A·NCT00855439·46 enrolled

Hyperglycemia1 trial

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Terminated·NNorthwestern University·Phase 4·NCT03511521·3 enrolled

Type 1 Diabetes Mellitus1 trial

A Study in Participants With Type 1 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01481779·455 enrolled

Remission1 trial

Remission Through Early Monitored Insulin Therapy - Duration Month

Completed·SSandra Sobel·Phase 4·NCT03670641·10 enrolled

Adolescent1 trial

One Year Glargine Treatment in CFRD Children and Adolescents

Completed·FFederico II University·Phase 4·NCT00483769·20 enrolled

Elderly1 trial

Simplified Insulin Protocol Using Lantus in Elderly

Completed·JJoslin Diabetes Center·Phase 4·NCT01480843·65 enrolled

Lip1 trial

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

Completed·—·Phase 4·NCT05579119·76 enrolled

SMA1 trial

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00551538·15 enrolled

Endothelial Function1 trial

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Completed·UUniversity of Palermo·Phase 4·NCT03824002·92 enrolled

T1DM1 trial

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Completed·WWockhardt·Phase 1·NCT01357603·111 enrolled

Elderly Patients1 trial

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Completed·EEmory University·Phase 4·NCT01240200·49 enrolled

Unspecified2 trials

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Completed·UUniversity of Aarhus·Phase 3·NCT01461616·19 enrolled

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Completed·UUniversity of Padova·Phase 4·NCT00699686·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Glargine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glargine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glargine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Glargine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes8 trials

Type 1 Diabetes4 trials

Type 2 Diabetes Mellitus3 trials

Diabetic Ketoacidosis3 trials

Medication2 trials

Diagnosis1 trial

Tics1 trial

Effectiveness1 trial

Efficacy and Safety1 trial

Diabetes Mellitus1 trial

Diabetic Neuropathy1 trial

Hyperglycemia1 trial

Type 1 Diabetes Mellitus1 trial

Remission1 trial

Adolescent1 trial

Elderly1 trial

Lip1 trial

SMA1 trial

Endothelial Function1 trial

T1DM1 trial

Elderly Patients1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News